Increasing Number of Cancer Patients Fuels the Growth of the Global mRNA Vaccines and Therapeutics Market

According to MarkNtel Advisors’ research report, “Global mRNA Vaccines and Therapeutics Market Analysis, 2021,” the market is likely to witness around 13% CAGR during 2021-26. mRNA Vaccines and Therapeutics are gaining immense popularity, owing to their crucial advantages over the conventional vaccination approach. The booming demand for mRNA vaccines is most prominently because they are inexpensive and easy to develop. Further, the rising occurrence of chronic diseases is another crucial aspect bolstering the demand for mRNA vaccines, thereby likely to propel the overall market growth in the forecast period.

Get a sample copy of the market analysis: https://www.marknteladvisors.com/query/request-sample/global-mrna-vaccines-and-therapeutics-market.html

Key Questions Answered in the Study
1. What are the current and future trends in the Global mRNA Vaccines and Therapeutics market?
2. How has the industry been evolving in terms of geography and services adoption?
3. How has the competition been shaping across the countries, followed by their comparative factorial indexing?
4. What are the key growth drivers and challenges for the Global mRNA Vaccines and Therapeutics market?
5. What are the customer orientation, purchase behavior, and expectations from the Global mRNA Vaccines and Therapeutics market service providers across various regions?

Nucleoside to Dominate Global mRNA Vaccines and Therapeutics Market with the Largest Share
Based on the mRNA Type, the market segments into Nucleoside-Modified mRNA (mod RNA), Unmodified mRNA, and Self-Amplifying mRNA. Of these, the Nucleoside-Modified mRNA (mod RNA) type acquired the largest share in the Global mRNA Vaccines and Therapeutics Market in the previous few years owing to its effectiveness to elicit a high immune response, particularly for life-threatening viral infections.

Further, the mounting adoption of Nucleoside-Modified mRNA by pharmaceutical companies to develop COVID-19 vaccines and the recent approval by the regulatory authorities to produce Nucleoside-Modified mRNA (mod RNA)-based vaccines are other essential aspects augmenting the overall market growth.

For more detailed overview: https://www.marknteladvisors.com/research-library/global-mrna-vaccines-and-therapeutics-market.html

“Global mRNA Vaccines and Therapeutics Market Analysis, 2021” provides comprehensive, qualitative, and quantitative insights on the market potential, key factors impacting the market growth, hotspots, and opportunities available for mRNA Vaccines and Therapeutics providers across the globe. Moreover, the report also encompasses the key strategic imperatives for competitors' success and strategic factorial indexing to measure their capabilities on 16 parameters, which will help companies formulate 'Go to Market' strategies and identify the blue ocean for their offerings.


BNT162b2 Vaccine Attained Highest Share in the Global mRNA Vaccines and Therapeutics Market
Based on the COVID mRNA Application, the market divides into Commercialized Vaccine and Pipeline Vaccine. The Commercialized Vaccine segment further bifurcates into mRNA-1273 and BNT162b2. Among these, the BNT162b2 vaccine held the largest market share in the previous years, primarily due to the surging number of COVID-19 patients.

BNT162b2 vaccine is developed jointly by BioNTech SE and Pfizer Inc. Additionally, Pfizer's strong global presence in terms of supply & funds entwined with its superior efficacy & safety are also aiding the segment growth, reveals MarkNtel Advisors in their research report, “Global mRNA Vaccines and Therapeutics Market Analysis, 2021.”

According to MarkNtel Advisors, the major leading players in the Global mRNA Vaccines and Therapeutics Market are Arcturus Therapeutics Holdings Inc., BioNTech, CureVac N.V., ethris GmbH, Gennova Biopharmaceuticals Ltd, GlaxoSmithKline plc, Moderna, Pantherna Therapeutics GmbH, Pfizer, Providence Therapeutics, Providence Therapeutics, Silence Therapeutics, and Verve Therapeutics, Inc.

Market Segmentation:
1. By mRNA Type (Nucleoside-Modified mRNA (mod RNA), Unmodified mRNA, Self-Amplifying mRNA)
2. By Application Type (COVID mRNA Application [Commercialized Vaccine {mRNA-1273, BNT162b2}, Pipeline Vaccines {CVnCoV, LUNAR-COV19, MRT5500, DS-5670}] Non-COVID mRNA Application [Immuno-Oncology, Cardiology, Endocrinology, Haematology, Other infectious & rare diseases])
3. By End-User (Hospitals & healthcare Clinics, Research Organization & Institutions, Others)
4. By Region (North America, Latin America, Europe, Asia-Pacific, Middle East & Africa)
5. By Country (U.S, Canada, Brazil, Argentina, Mexico, Germany, France, The U.K, Spain, Italy, China, India, Japan, Australia, South Korea, Saudi Arabia, UAE, South Africa)
6. By Competitors (Arcturus Therapeutics Holdings Inc., BioNTech, CureVac N.V., ethris GmbH, Gennova Biopharmaceuticals Ltd, GlaxoSmithKline plc, Moderna, Pantherna Therapeutics GmbH, Pfizer, Providence Therapeutics, Providence Therapeutics, Silence Therapeutics, Translate Bio, Versameb AG, Verve Therapeutics, Inc.)

MarkNtel Advisors
1147 88AVE, Delta, British Columbia, BC,V4C,3B8, CANADA
Email: sales@marknteladvisors.com
Tel: +1 604 800 2671
Website: https://www.marknteladvisors.com

MarkNtel Advisors is a leading research, consulting and data analytics firm that provides a wide range of strategic reports on diverse industry verticals to a substantial and varied client base that includes multinational corporations, financial institutions, governments, and individuals.

We specialize in niche industries and emerging geographies to support our clients in the formulation of strategies viz. Go to Market (GTM), product development, feasibility analysis, project scoping, market segmentation, competitive benchmarking, market sizing & forecasting, trend analysis, etc. in around 15 industry verticals to enable our clients in identifying attractive investment opportunities and maximizing ROI through an early mover advantage.

This release was published on openPR.